Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis

被引：16

作者：

Laskari, Katerina ^{[1
]}

Tzioufas, Athanasios G. ^{[1
]}

Antoniou, Anna ^{[2
]}

Moutsopoulos, Haralampos M. ^{[1
]}

机构：

[1] Univ Athens, Sch Med, Dept Pathophysiol, GR-11527 Athens, Greece

[2] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, GR-11527 Athens, Greece

来源：

JOURNAL OF RHEUMATOLOGY | 2011年 / 38卷 / 07期

关键词：

LUPUS NEPHRITIS; MAINTENANCE TREATMENT; MYCOPHENOLATE MOFETIL; CLASSIFICATION; ERYTHEMATOSUS; THERAPY;

D O I：

10.3899/jrheum.101249

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Objective. To determine the timing for safe reduction of mycophenolate mofetil (MMF) dose during remission-maintenance therapy of proliferative lupus nephritis. Methods. The study population consisted of 44 patients evaluated retrospectively; MMF dose was empirically tapered in 18/44 patients until the latest observation. Results. Patients reducing MMF <= 18 months after remission/complete remission had a 6.8-fold/6.3-fold higher risk of relapse compared to those taking a stable dose (p = 0.001, p = 0.011, respectively). Reducing MMF later than 18 months was not associated with increased relapse rates. Conclusion. Reducing MMF > 1.5 years after remission/complete remission seems to warrant drug tapering without increased risk of disease flare in proliferative lupus nephritis. (J Rheumatol First Release April 15 2011; doi:10.3899/jrheum.101249)

引用

页码：1304 / 1308

页数：5

共 50 条

[1] Longterm Followup After Tapering Mycophenolate Mofetil During Maintenance Treatment for Proliferative Lupus Nephritis
Jourde-Chiche, Noemie
Daugas, Eric
JOURNAL OF RHEUMATOLOGY, 2011, 38 (11) : 2490 - 2490
[2] Mycophenolate mofetil for the induction and maintenance treatment of lupus nephritis
Gonzalez-Rivera, Tania C.
McCune, Joseph
IMMUNOTHERAPY, 2011, 3 (12) : 1431 - 1440
[3] Treatment of Lupus Nephritis by Mycophenolate Mofetil
Rabrenovic, Violeta
Poskurica, Mileta
Kovacevic, Zoran
Nesic, Vidosava
Savin, Marina
Mitic, Branka
Dimkovic, Nada
Cuckovic, Cedomir
Vujic, Danica
Pljesa, Steva
Perunicic-Pekovic, Gordana
Curic, Slobodan
Mitic, Igor
Ratkovic, Marina
Marinkovic, Jelena
Jovanovic, Dragan
KIDNEY & BLOOD PRESSURE RESEARCH, 2010, 33 (04) : 297 - 303
[4] Defining the Role of Mycophenolate Mofetil in the Treatment of Proliferative Lupus Nephritis
Oliver Dr Lenz
Alessia Fornoni
Gabriel Contreras
Drugs, 2005, 65 : 2429 - 2436
[5] Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide
Contreras, G
Tozman, E
Nahar, N
Metz, D
LUPUS, 2005, 14 : S33 - S38
[6] Mycophenolate mofetil versus intravenous cyclophosphamide for induction treatment of proliferative lupus nephritis in a Japanese population: a retrospective study
Onishi, Akira
Sugiyama, Daisuke
Tsuji, Go
Nakazawa, Takashi
Kogata, Yoshinori
Tsuda, Kosaku
Naka, Ikuko
Nishimura, Keisuke
Misaki, Kenta
Kurimoto, Chiyo
Hayashi, Hiroki
Kageyama, Goichi
Saegusa, Jun
Sugimoto, Takeshi
Kawano, Seiji
Kumagai, Shunichi
Morinobu, Akio
MODERN RHEUMATOLOGY, 2013, 23 (01) : 89 - 96
[7] Lupus nephritis: treatment with mycophenolate mofetil
Kapitsinou, PP
Boletis, JN
Skopouli, FN
Boki, KA
Moutsopoulos, HM
RHEUMATOLOGY, 2004, 43 (03) : 377 - 380
[8] Concentration-controlled treatment of lupus nephritis with mycophenolate mofetil
Daleboudt, G. M. N.
Reinders, M. E. J.
den Hartigh, J.
Huizinga, T. W. J.
Rabelink, A. J.
de Fijter, J. W.
Berger, S. P.
LUPUS, 2013, 22 (02) : 171 - 179
[9] Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis
Rezaieyazdi, Zahra
Tavakoli, Tahmine
Khajehdaluee, Mohammad
Honarmand, Shahram
SPRINGERPLUS, 2014, 3
[10] Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring
Zabotti, A.
Baraldo, M.
Quartuccio, L.
Sacco, S.
De Marchi, G.
De Vita, S.
CLINICAL RHEUMATOLOGY, 2015, 34 (01) : 171 - 174

← 1 2 3 4 5 →